Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT Combined with Biologicals for IBD
NCT07149441Active, not recruiting
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- Aug 2025
- Primary completion
- Sep 2028
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Randomised, open-label trial of allogeneic fecal microbiota in ulcerative colitis (UC) and Crohn's disease (2 arms), sponsored by Shanghai Tenth People's Hospital. Primary endpoints: Endoscopic remission rate at 52 weeks and Clinical remission rate at 52 weeks. Started Aug 2025; status: active, not recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT07149441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07149441.